MicroRNAs are small noncoding RNAs that posttranscriptionally control gene expression by targeting mRNAs. Distinct microRNAs regulate stem and progenitor cell functions, thereby modulating cell survival and homing or controlling differentiation and maturation. Experimental studies additionally show that microRNAs regulate endogenous repair and might potentially be useful to enhance the regeneration of the heart. This review summarizes the current studies that address the use of microRNAs to either improve cellular therapies or that might be targeted for enhancing endogenous tissue repair and regeneration after myocardial infarction. (Arterioscler Thromb Vasc Biol. 2013;33:1739-1746.) 
C oronary artery disease is a progressive disease with a high morbidity and mortality worldwide. Despite improved primary prevention, as well as interventional and pharmacological therapies, the incidence of heart disease is further increasing particularly because of metabolic disorders and an extended life span. After an acute myocardial infarction, the death of cardiomyocytes, which cannot sufficiently be replaced by endogenous regeneration, renders the heart susceptible for unfavorable remodeling and heart failure. Stem/ progenitor cell therapies have been considered as promising options to compensate for the loss of cardiomyocytes. Various adult stem/progenitor cells were used in experimental and clinical trials, 1, 2 and bone marrow-derived proangiogenic cells and mesenchymal stromal cells were shown to augment the recovery after ischemia in experimental models. The clinical trials overall showed a modest improvement in heart function 3, 4 ; however, the results had been heterogeneous and larger scale trials are ongoing to test whether cell therapy with bone marrow-derived cells indeed can improve patient survival. In addition, cardiac stem cells recently showed promising results in phase I/II clinical trials. 5, 6 Embryonic or induced pluripotent stem cells so far have shown the highest capacity to replace dead myocardium; however, their clinical use is hampered by potential safety hurdles that first need to be addressed. 7
This article accompanies the ATVB in Focus: MicroRNAs: From Basic Mechanisms to Clinical
Application in Cardiovascular Medicine series that was published in the February 2013 issue.
MicroRNAs (miRNAs/miRs) are small noncoding RNAs that control gene expression by binding to target mRNAs and thereby inducing translational repression or mRNA degradation. 8 MiRNAs are processed by several maturation steps mediated by protein complexes, including the RNases Drosha and Dicer, and the mature miRNAs are incorporated into the RNA-inducing silencing complex to target mRNAs. About 2000 miRNAs have been identified in humans, and miRNAs are known to influence the expression of ≈30% of the genes. miRNAs contribute to embryonic development and tissue homeostasis but even more profoundly regulate pathophysiological processes. [9] [10] [11] Tissue injury, as for example myocardial infarction, profoundly disturbs the expression of miRNAs. 12 MiRNAs also have an important influence on stem cells; several miRNA families were shown to be required to maintain pluripotency of embryonic stem cells, 13, 14 and recent studies demonstrated that the combined overexpression of miRNAs is sufficient to induce pluripotent stem cells. 13, 14 Although the downregulation of pluripotency-related miRNAs is required for differentiation, the differentiation and maturation of stem cells are associated with the increased expression of lineageenriched miRNAs. 13, 14 Finally, stem/progenitor cell functions are controlled by miRNAs. 13 Here, we review the current studies that address the use of miRNAs to either improve cellular therapies or that might be targeted for enhancing endogenous tissue repair and regeneration after myocardial infarction.
MiRNAs for Cell Enhancement
Various adult progenitor cells, embryonic stem cells, or reprogrammed cells were successfully used to augment heart function after ischemia. 1 However, the experience in clinical trials and longer term follow-up studies in experimental models revealed several major challenges: (1) particularly, bone marrow-derived cells showed an impairment in function and survival when isolated from aged patients with chronic disease; (2) the homing and long-term integration of cells applied was poor in most studies 15 ; and (3) a direct cardiac regeneration by replacement of cardiomyocytes was modest or absent in the majority of studies testing adult progenitor cell populations so far. 16 Therefore, several attempts were made to improve cell therapy by interfering with cell function, homing, survival, or differentiation. 15 Because miRNAs change gene expression networks and can be easily inhibited by small molecules, they might be interesting candidates to ex vivo treat cells before transplantation. Various miRNAs are modulated by cardiovascular risk factors and disease, and reversal of the deregulated miRNAs might improve the functional capacity of cells in patients with coronary artery disease [17] [18] [19] [20] (Figure 1 ).
Improvement of Cell Survival and Function by MiRNAs
Cell survival was affected by several miRNA families in adult progenitor cells or proangiogenic cells. For example, miR-126 was used to augment the efficiency of transplanted cells. miR-126 was initially shown to be essential for angiogenic signaling in endothelial cells, but also improved cell survival and migration of mesenchymal stromal cells (MSCs) and proangiogenic bone marrow-derived cells. 17, [21] [22] [23] This may be particularly relevant for autologous cells because both, diabetes mellitus and heart failure, were shown to downregulate miR-126 levels in patient-derived cells. 17, 19, 24 Ex vivo overexpression of miR-126 in MSC or proangiogenic cells improved angiogenesis and augmented the recovery in experimental myocardial infarction models. 22, 23 MiR-126 is known to repress inhibitors of the phosphatidylinositol 3'-kinase (PI3K)/Akt pathway, which results in the activation of the prosurvival Akt signaling pathway, which promotes cell survival and might also enhance the release of paracrine factors as previously reported for Aktoverexpressing MSC. 25 Indeed, Huang et al 23 showed that overexpression of miR-126 augments the release of paracrine factors from MSC, which contributes to the improvement of repair after cell transplantation. Besides Akt, miR-126 controls the expression of the Notch ligand Delta-like 4 in MSC. By controlling this pathway, miR-126 does not only improve cell survival but also promotes tubulogenesis. 23 Interestingly, miR-126 seems not only to act as cell intrinsic regulator of cell functionality but is also released and acts in a paracrine manner to augment neovascularization. The cellular release of exosomes, which among other factors contain miRNAs, is known to mediate cell-to-cell communication between several cell types. [26] [27] [28] For example, exosomes derived from CD34 + cells improve neovascularization after ischemia. 29 A recent study now demonstrates that miR-126 is preferentially enriched in microvesicles derived from CD34 + cells compared with other cell types and contributes to the proangiogenic activity of the cell supernatants. 19 In addition, Cantaluppi et al 30 demonstrated that proangiogenic cells release miRNAs 126-and miR-296-containing microvesicles that induce angiogenesis in endothelial cells. An impaired expression of miR-126 was demonstrated in microvesicles isolated from supernatants of peripheral blood CD34 + cells from patients with diabetes mellitus, and overexpression of miR-126 restored the proangiogenic activity of diabetic CD34 + cells. 19 These findings are consistent with the lower circulating levels of miR-126 detected in patients with diabetes mellitus or coronary artery disease 31, 32 and overall may contribute to the known impaired neovascularization capacity observed in patients with diabetes mellitus.
MiR-34a represents a second example that is regulated during disease and affects the functional capacity and survival of cells used for cell therapy. miR-34a is profoundly induced by aging and in bone marrow-derived cells from patients with heart failure and its inhibition improved the survival of the cells in vitro. 20 Ex vivo treatment of bone marrow-derived mononuclear cells with miR-34a inhibitors augments the cell transplantation-induced improved functional recovery after acute myocardial infarction. 20 Vice versa, overexpression of miR-34a induced cells death 20 and worsened the proangiogenic activity of proanigogenic cells by increasing senescence. 33 In addition, miR-34a influenced apoptosis signaling by, for example, targeting the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) and it blocked cellular proliferation by repression of cell cycle regulators, such as cyclin D2 and cyclin-dependent kinases. 20, 34 In proangiogenic cells the histone deacetylase silent mating type information regulation 2 homolog 1 (SIRT1) was reported to be inhibited by miR-34a, which may additionally contribute to the detrimental function of miR-34a in vascular repair. 35, 36 MiRNAs also augmented cell survival and in vivo functional capacity of cardiac stem/progenitor cells. An interesting study tests the effect of individual miRNAs versus combinations and showed that the combination of 3 miRNAs, namely miR-21, miR-24, and miR-221, is more efficient to improve engraftment and survival of transplanted cardiac progenitor cells. 37 The above-mentioned miRNAs target the apoptotic protein Bim and thereby directly improve cell survival. 37 In addition, miR-155 overexpression repressed necrosis of cardiac stem cells. 38 Cellular senescence, which compromises cellular functions, can be regulated by miRNAs. Thus, miR-10a*, miR-21, and miR-34a increase senescence of proangiogenic cells, whereas the inhibition of these miRs improved angiogenesis. 33, 36, 39 Particularly, antagonizing miR-21 reduced reactive oxygen species production, 18 which can contribute to cellular dysfunction and senescence.
Several miRNAs modulated the migration of cells; miR-150 and miR-146 target the stromal cell-derived factor 1 (SDF-1) receptor chemokine receptor type 4 (CXCR4), which is essential for progenitor and proangiogenic cell homing to ischemic tissues, 40, 41 and miR-15a and miR-16 were recently shown to profoundly inhibit the migratory potential of proangiogenic cells isolated from patients with critical limb ischemia. 42 The targets of miR-15a/16 include the proangiogenic cytokine vascular endothelial growth factor (VEGF) and the Akt isoform-3 that contribute to the defective function of proangiogenic cells from patients with limb ischemia. 42 However, both miRNAs target a variety of antiapoptotic proteins that may have contributed to their detrimental effects as well.
Enhancement of Differentiation of Transplanted Stem/Progenitor Cells
Although embryonic stem cells can acquire a cardiac muscle cell phenotype and, therefore, might be useful to regeneration therapies, their integration, survival, and homing have been shown to be limited in some studies. 43 Moreover, the generation of fully mature differentiated cells is a major challenge. Recent studies now suggest that overexpression of miR-1 in embryonic stem cells enhanced cardiac differentiation after transplantation, 44, 45 a finding which is consistent with previous in vitro reports showing an increase in cardiac lineage commitment by the overexpression of cardiac miRs, such as miR-1 or miR-499. [46] [47] [48] Whether such an approach might be also useful to improve the cardiac differentiation capacities of adult progenitor cells deserves further studies. Interestingly, the miR-1-overexpressing embryonic stem cells also reduced apoptosis of the host cardiomyocytes suggesting that miRNAs can exhibit pleiotropic effects, which together may lead to a better tissue repair.
In summary, ex vivo regulation of several miRNAs by anti-miRs or miR mimics can improve cell survival and affects the functions of several stem/progenitor cells and proangiogenic cells that are used for therapeutic augmenting cardiac repair and regeneration. The engineering of cells by ex vivo treatment with anti-miR mimics might be a promising tool to improve the success of cell therapy.
MiRNAs and Postischemic Protection
The recovery of heart function after ischemia is influenced by various processes and can be enhanced by blocking cardiomyocyte cell death or by improving tissue perfusion. In addition, the invasion of inflammatory cells enhances tissue damage; however, inflammation is also required for wound healing and tissue remodeling. During later stages, the replacement of dead cardiomyocytes by fibrotic tissue contributes to the impairment of heart function. Given the multiple functions of miRNAs, it does not come as a surprise that all of these processes are regulated by diverse miRNAs.
Prevention of Cardiomyocyte Death
The miR-15 family, which comprises 6 closely related miRs, is increased in murine and pig hearts within 24 hours after ischemia/reperfusion injury. 49 Inhibition of miR-15 family members reduced hypoxia and hypoxia/reoxygenation-induced cardiomyocyte cell death 49 and improved mitochondrial function and ATP levels. 50 In vivo, miR-15 inhibition by short locked nucleic acid-based anti-miRs (so called tiny miRs) reduces infarct size in mice after ischemia/reperfusion injury. 49 MiR-15 targets the antiapoptotic protein Bcl-2 and the mitochondrial protective protein ADP-ribosylation factor-like 2 in cardiomyocytes. 49, 50 A similar effect was reported for the miR-34 family, which is induced by myocardial infarction and promotes cardiomyocyte cell death. [51] [52] [53] Inhibition of miR-34 family members improved cardiac function after acute myocardial infarction. 53, 54 Moreover, a cardioprotective effect was observed during cardiac aging. 54 MiR-34a targets SIRT1, which is a vasculo-and cardioprotective deacetylase, and its derepression contributes to the antiapoptotic effects of miR-34 inhibition. In addition, the protein phosphatase 1 regulator PNUTS (or serine/threonineprotein phosphatase 1 regulatory subunit 10 [PPP1R10]), a protein involved in DNA damage response and telomere shortening, is repressed by miR-34 (Figures 1 and 2) . 52, 54 Among the miRNAs that are upregulated after cardiac stress, miR-214 exhibits a protective function. miR-214 is downregulated during embryonic development and further decreased in adult mice, but it is reexpressed within 7 days after ischemia/ reperfusion injury. 55 Genetic deletion of miR-214 aggravated ischemic/reperfusion-induced cell death and induced a further deterioration of heart function. 55 This effect was at least in part mediated by a repression of the sodium/calcium exchanger Ncx1, which under stress conditions contributes to calcium overload. 55 Three miR-214 targets, namely cyclophilin D-a regulator of the mitochondrial permeability transition porethe proapoptotic protein Bim, and the hypertrophy-regulating Ca 2+ /calmodulin-dependent protein kinases I (CaMKIId), were identified in the hearts and all may contribute to the observed protective effect of this miRNA. 55 The proapoptotic protein Bim is additionally targeted by miR-24, which is downregulated after acute myocardial infarction. 56 Overexpression of miR-24 reduced cardiomyocyte apoptosis in vitro and in vivo and attenuated infarct size and improved heart function after myocardial infarction. 56 Moreover, miR-20a, which is part of the miR17-92 cluster, inhibits apoptosis of cardiomyocytes. 57
Improvement of Perfusion/Angiogenesis
MiR-92a was the first miRNA shown to control neovascularization after acute myocardial infarction. 58 Inhibition of miR-92a enhanced endothelial cell migration and sprouting in cell culture studies. 58, 59 In vivo, miR-92a is increased within the first days after infarction and its inhibition increased capillary density and improved heart function after myocardial infarction. 58 In endothelial cells, miR-92a targets integrin a5, 58 which prevents endothelial cell apoptosis and is important for vessel maturation. 60 In addition, several vasculoprotective genes were repressed by miR-92a, such as SIRT1, which prevent endothelial NO synthase acetylation and inactivation. 61 In addition, various miRNAs are meanwhile identified as regulators of angiogenesis. 62 Most studies, however, did not test the function in myocardial infarction. Among the miRNAs that are tested for their potential role in regulating cardiac neovascularization, miR-24 was shown to inhibit angiogenesis in various models, and antagomirs directed against miR-24 improved the recovery after acute myocardial infarction by targeting the endothelium-enriched transcription factor GATA2 and the p21-activated kinase 4. 63 The improvement of cardiac function by antagomirs directed against miR-24 is counterintuitive to the above-discussed findings that miR-24 overexpression attenuates infarct size and improved heart function. 56 However, recent studies showed that antagomirs directed against miR-24 protected against the transition from hypertrophy to decompensated heart failure by interfering with excitation-contraction coupling after aortic constriction. 64 Further studies need to clarify the role of miR-24 in neovascularization versus direct cardioprotection. One may speculate that the inhibitors target different cells and affect different pathways compared with the unphysiological overexpression of the miRNA.
The miR-15 family inhibits angiogenesis after hind-limb or myocardial ischemia, 49, 65, 66 which in combination with the induction of cardiac cell death may contribute to the profound functional effects of miR-15 inhibitors in experimental myocardial infarction discussed above.
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Prevention of Fibrosis
MiR-29 is repressed by cardiac stressors, such as aortic banding, and is reduced after acute myocardial infarction. 12, 67 Interestingly, the miR-29 family targets multiple proteins involved in fibrosis, including multiple collagens, fibrillins, and elastin. 12, 68 Thus, overexpression of miR-29 might be an interesting therapeutic option to block the fibrotic response. MiR-21 was among the first miRNAs that was shown to be upregulated after acute myocardial infarction. 12 Subsequent studies blocked miR-21 by antagomirs and reported that this enhanced cardiac function and prevents cardiac fibrosis. 69 However, genetic deletion of miR-21 or blocking of miR-21 with shorter locked nucleic acid-based anti-miRs had no effect in other studies. 70 Although ample evidence supports a direct profibrotic function of miR-21, 71 it might have additional functions in other cells. For examples, miR-21 was shown to prevent H 2 O 2 -induced cardiomyocyte cell death. 72 Likewise, overexpression of miR-21 via adenovirus-expressing miR-21 inhibited cardiomyocyte apoptosis and decreased myocardial infarct size after acute myocardial infarction. 73 These studies showed that miR-21 targets the proapoptotic geneprogrammed cell death 4 and the activator protein 1 pathway, which play a crucial role in cardiomyocyte cell death. 74 MiR-101 has also been implicated in cardiac fibrosis. It is downregulated after 4 weeks of acute myocardial infarction and forced overexpression of miR-101a/b, to compensate for the long-term repression of this miR, inhibited proliferation of cardiac fibroblasts, and reduced collagen production. 75 Mechanistically, miR-101 was targeting the c-fos and transforming growth factor-β1 signaling pathways. 75
MiRNAs and Endogenous Cardiac Regeneration
Attempts to truly regenerate the heart have been challenging particularly because the strategy of exogenous cell therapy faced multiple problems, including the limited survival, integration, and differentiation capacity of various tested cell types. 15, 76 Although the adult mammalian heart is one of the least regenerative organs, recent studies suggest that activation of endogenous cardiac regeneration might be possible by augmenting cardiomyocyte proliferation or by reprogramming fibroblasts into functional cardiomyocytes. MiRNAs might be suitable to trigger or enhance both processes. 9, 77 Moreover, a combination of miRNAs can be used to turn fibroblasts to induced pluripotent stem cells. 13
MiRNAs and Cardiomyocyte Proliferation
MiRNA expression profiles in neonatal mouse hearts, which possess the capacity to regenerate at least until day 7, showed that several miRNAs are regulated during postnatal cardiac development. Among the highly regulated miRNAs are members of the miR-15 family, particularly miR-195, which is upregulated within the first days after birth. 78, 79 The miR-195 upregulation coincides with the postnatal transition of the heart toward cell cycle arrest, suggesting that it might contribute to the mitotic arrest of cardiomyocytes after birth. Indeed, inhibition of miR-15 family members increased the rate of proliferating cardiomyocytes up to day 12 after birth, 78 whereas overexpression of miR-195 impaired cardiomyocyte proliferation and induced ventricular hypoplasia and septal defects. 78 The miR-15 family members profoundly modulated the expression of proliferation-associated genes in cardiomyocytes, a finding that is consistent with the antiproliferative activity of miR-15 in other cell types. 80 Specifically, checkpoint kinase 1 was identified as a direct target of miR-15 in cardiomyocytes. 78 A functional miRNA screen recently confirmed that miR-15 inhibits cardiomyocyte proliferation. 81 Furthermore, various additional miRNAs were identified that control cardiomyocyte proliferation. Two of these miRNAs, namely miR-590 and miR-199a, were further validated and the study shows that overexpression of each of these miRNAs promotes cardiomyocyte proliferation in neonatal and adult mice. 81 Interestingly, viral overexpression of the miRNAs enhanced cardiomyocyte proliferation and preserved long-term cardiac function after permanent ligation of the coronary artery. 81 Together, at least in mouse models, miRNAs may be useful to reverse the cell cycle blockade of adult cardiomyocytes. Further studies have to evaluate the function in adult human cardiomyocytes.
MiRNAs and Direct Reprogramming
Besides inducing cardiomyocyte proliferation, miRNAs may be also useful to augment direct cardiac reprogramming. Direct cardiac reprogramming of fibroblasts has first been achieved by combined overexpression of cardiac transcription factors, such as GATA4, myocyte-specific enhancer factor 2C (MEF2C), and T-box transcription factor (TBX5), 82, 83 or the 3 factors with the addition of Hand2. 84 As discussed above, cardiac-enriched miRNAs were shown to facilitate cardiac differentiation of stem cells. 44, 46, 47, 85 Therefore, Jayawardena et al 86 tested whether miRNAs might be helpful to convert fibroblasts into cardiomyocyte-like cells. Indeed, the combination of several miRNAs, namely miR-1, miR-133, miR-208, and miR-499, augmented cardiac marker gene expression in fibroblasts in vitro. Overexpression of the miR cocktail also increased the reprogramming of cardiac fibroblasts into cardiomyocytes in vivo as shown by using lineage tracing. 86 Although the extent of converting fibroblasts into cardiomyocytes in principle is rather low and even more challenging in human cells, further studies may overcome these hurdles by combining transcription factors with miRNAs and small molecules to optimize this promising therapeutic strategy.
Outlook
Various experimental studies provide convincing evidence that miRNAs might be targeted to improving cell therapy or enhancing endogenous repair processes. Despite these encouraging data, the development of miRNA therapeutics faces several challenges and questions; although miRNA inhibition is very efficient, 87 overexpression of miRNAs is not yet established with small molecules and requires the use of vectors. Gene therapy recently gained back attention with the first gene therapy being approved in Europe 88 and promising results being reported for cardiac gene therapy with the adenoassociated virus-vectors 89 ; however, it is still not at a stage that would allow easy clinical translation. Second, the biology of miRNAs is far from being understood and the moderate repression of multiple targets by miRNAs requires a system 
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August 2013 biology approach to identify the full impact on the gene expression networks. Some miRNAs target patterns of genes with a common biological function (eg, miR-29 targeting various matrix proteins); however, other miRNAs target genes with antagonistic functions (eg, pro-and antiapoptotic genes) making it even more complicated to understand the biological activities. Finally, targeting ubiquitously expressed miRNAs may face challenges with respect to unwanted side effects in other cells or tissue. Therefore, cell type-specific delivery strategies may be required in some cases. However, the promising results from recent phase II clinical trials documenting not only the safety and feasibility but also the biological function of anti-miRs for the treatment of hepatitis encourage the development of miRNA therapeutics for the treatment of cardiovascular diseases.
